By Professor Alexander Swarbrick

Journal articles

Kim HJ; Ruan T; Swarbrick A, 2025, 'Pan-Cancer Spatial Profiling Reveals Conserved Subtypes and Niches of Cancer-Associated Fibroblasts', Cancer Research, 85, pp. 2555 - 2557, http://dx.doi.org/10.1158/0008-5472.CAN-25-2181

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JM; Poulos RC; Wu Y; Dausmann M; MacKenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; DeFazio A; Filipits M; Flynn PJ; Graham JD; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu JJ; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated deep learning enables cancer subtyping by proteomics.', Cancer Discov, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Bai X; Quek C; Al-Eryani G; Ramkomuth S; Baldwin L; Tian J; Adegoke NA; Vergara IA; Newell F; Harvey K; Reeves J; Spillane AJ; Waddell N; Lo SN; Menzies AM; da Silva IP; Palendira U; Long GV; Scolyer RA; Swarbrick A; Wilmott JS, 2025, 'Abstract 179: Spatial and multiomics analysis reveals immune interactions as key drivers of immunotherapy outcomes in melanoma patients with in-transit metastases', Cancer Research, 85, pp. 179 - 179, http://dx.doi.org/10.1158/1538-7445.am2025-179

Parsons A; Colon ES; Spasic M; Kurt BB; Koca B; Manjunath M; Lineker D; Patel A; Snow C; Swarbrick A; Freedman R; Mittendorf E; van Galen P; McAllister S, 2025, 'Abstract 2562: Cell populations in human breast cancers are molecularly and biologically distinct with age', Cancer Research, 85, pp. 2562 - 2562, http://dx.doi.org/10.1158/1538-7445.am2025-2562

Vandenbempt V; Roach M; Mohenska M; Wise K; Wang T; Harvey K; Jensen K; Swarbrick A; Polo JM; Gurzov EN; Martelotto LG, 2025, 'Validation of single-cell transcriptomic profiles from Illumina and MGI Tech sequencing platforms', FEBS Letters, http://dx.doi.org/10.1002/1873-3468.70087

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.2591

Haggstrom L; Middleton K; Segara D; Ong A; Bingham J; Carson E-K; Kiely BE; Sabanathan D; Saw K; Siu MT; Serrano A; Eshraghi L; O'Toole S; Mann B; Lindeman GJ; Swarbrick A; Tilley W; Coates AS; Parker A; Lim E, 2025, 'The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.', Journal of Clinical Oncology, 43, pp. 513 - 513, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.513

Mo J; Zhang H; Swarbrick A, 2025, 'TiME for a change: The tumor microenvironment as the missing piece in cancer therapeutics.', PLoS Biol, 23, pp. e3003276, http://dx.doi.org/10.1371/journal.pbio.3003276

Wang T; Roach MJ; Harvey K; Morlanes JE; Kiedik B; Al-Eryani G; Greenwald A; Kalavros N; Dezem FS; Ma Y; Pita-Juarez YH; Wise K; Degletagne C; Elz A; Hadadianpour A; Johanneson J; Pakiam F; Ryu H; Newell EW; Tonon L; Kohlway A; Drennon T; Abousoud J; Stott R; Lund P; Durruthy J; Vallejo AF; Li W; Salomon R; Kaczorowski D; Warren J; Butler LM; O’Toole S; Plummer J; Vlachos IS; Lundeberg J; Swarbrick A; Martelotto LG, 2024, 'snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives', Communications Biology, 7, http://dx.doi.org/10.1038/s42003-024-07043-2

Chen J; Larsson L; Swarbrick A; Lundeberg J, 2024, 'Spatial landscapes of cancers: insights and opportunities', Nature Reviews Clinical Oncology, 21, pp. 660 - 674, http://dx.doi.org/10.1038/s41571-024-00926-7

Quek C; Pratapa A; Bai X; Al-Eryani G; Pires da Silva I; Mayer A; Bartonicek N; Harvey K; Maher NG; Conway JW; Kasalo RJ; Ben Cheikh B; Braubach O; Palendira U; Saw RPM; Stretch JR; Shannon KF; Menzies AM; Scolyer RA; Long GV; Swarbrick A; Wilmott JS, 2024, 'Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy', Cell Reports, 43, http://dx.doi.org/10.1016/j.celrep.2024.114392

Pereira BA; Ritchie S; Chambers CR; Gordon KA; Magenau A; Murphy KJ; Nobis M; Tyma VM; Liew YF; Lucas MC; Naeini MM; Barkauskas DS; Chacon-Fajardo D; Howell AE; Parker AL; Warren SC; Reed DA; Lee V; Metcalf XL; Lee YK; O'Regan LP; Zhu J; Trpceski M; Fontaine ARM; Stoehr J; Rouet R; Lin X; Chitty JL; Porazinski S; Wu SZ; Filipe EC; Cadell AL; Holliday H; Yang J; Papanicolaou M; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Vennin C; Yin J; Dew AB; McMillan PJ; Goldstein LD; Deveson IW; Croucher DR; Samuel MS; Sim HW; Batten M; Chantrill L; Grimmond SM; Gill AJ; Samra J; Jeffry Evans TR; Sasaki T; Phan TG; Swarbrick A; Sansom OJ; Morton JP; Pajic M; Parker BL; Herrmann D; Cox TR; Timpson P, 2024, 'Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response', Science Advances, 10, http://dx.doi.org/10.1126/sciadv.adl1197

Filipe EC; Velayuthar S; Philp A; Nobis M; Latham SL; Parker AL; Murphy KJ; Wyllie K; Major GS; Contreras O; Mok ETY; Enriquez RF; McGowan S; Feher K; Quek LE; Hancock SE; Yam M; Tran E; Setargew YFI; Skhinas JN; Chitty JL; Phimmachanh M; Han JZR; Cadell AL; Papanicolaou M; Mahmodi H; Kiedik B; Junankar S; Ross SE; Lam N; Coulson R; Yang J; Zaratzian A; Da Silva AM; Tayao M; Chin IL; Cazet A; Kansara M; Segara D; Parker A; Hoy AJ; Harvey RP; Bogdanovic O; Timpson P; Croucher DR; Lim E; Swarbrick A; Holst J; Turner N; Choi YS; Kabakova IV; Philp A; Cox TR, 2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, 11, http://dx.doi.org/10.1002/advs.202307963

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2024, 'Erratum: miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma (Molecular Therapy (2022) 30(3) (1119–1134), (S1525001622000041), (10.1016/j.ymthe.2022.01.004))', Molecular Therapy, 32, pp. 2031 - 2033, http://dx.doi.org/10.1016/j.ymthe.2024.05.008

Meyer B; Stirzaker C; Ramkomuth S; Harvey K; Chan B; Lee CS; Karim R; Deng N; Avery-Kiejda KA; Scott RJ; Lakhani S; Fox S; Robbins E; Shin JS; Beith J; Gill A; Sioson L; Chan C; Krishnaswamy M; Cooper C; Warrier S; Mak C; Rasko JEJ; Bailey CG; Swarbrick A; Clark SJ; O'Toole S; Pidsley R, 2024, 'Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma', Journal of Pathology, 262, pp. 480 - 494, http://dx.doi.org/10.1002/path.6250

Ciriello G; Magnani L; Aitken SJ; Akkari L; Behjati S; Hanahan D; Landau DA; Lopez-Bigas N; Lupiáñez DG; Marine JC; Martin-Villalba A; Natoli G; Obenauf AC; Oricchio E; Scaffidi P; Sottoriva A; Swarbrick A; Tonon G; Vanharanta S; Zuber J, 2024, 'Cancer Evolution: A Multifaceted Affair', Cancer Discovery, 14, pp. 36 - 48, http://dx.doi.org/10.1158/2159-8290.CD-23-0530

Swarbrick A; Fernandez-Martinez A; Perou CM, 2024, 'Gene-Expression Profiling to Decipher Breast Cancer Inter-and Intratumor Heterogeneity', Cold Spring Harbor Perspectives in Medicine, 14, http://dx.doi.org/10.1101/cshperspect.a041320

Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W, 2023, 'Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity', EMBO Molecular Medicine, 15, http://dx.doi.org/10.15252/emmm.202317737

Tran KA; Addala V; Johnston RL; Lovell D; Bradley A; Koufariotis LT; Wood S; Wu SZ; Roden D; Al-Eryani G; Swarbrick A; Williams ED; Pearson JV; Kondrashova O; Waddell N, 2023, 'Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures', Nature Communications, 14, http://dx.doi.org/10.1038/s41467-023-41385-5

Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR, 2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571

Vail ME; Farnsworth RH; Hii L; Allen S; Arora S; Anderson RL; Dickins RA; Orimo A; Wu SZ; Swarbrick A; Scott AM; Janes PW, 2023, 'Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression', Cancers, 15, http://dx.doi.org/10.3390/cancers15184646

Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A, 2023, 'Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer', Clinical Cancer Research, 29, pp. 1952 - 1968, http://dx.doi.org/10.1158/1078-0432.CCR-22-3350

Thai LM; O'Reilly L; Reibe-Pal S; Sue N; Holliday H; Small L; Schmitz-Peiffer C; Dhenni R; Wang-Wei Tsai V; Norris N; Yau B; Zhang X; Lee K; Yan C; Shi YC; Kebede MA; Brink R; Cooney GJ; Irvine KM; Breit SN; Phan TG; Swarbrick A; Biden TJ, 2023, 'β-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFβ receptor signaling', Iscience, 26, http://dx.doi.org/10.1016/j.isci.2023.106477

Quek C; Pratapa A; da Silva IP; Al-Eryani G; Mayer A; Bartonicek N; Harvey K; Braubach O; Saw RPM; Stretch J; Shannon KF; Menzies AM; Scolyer RA; Long GV; Swarbrick A; Wilmott JS, 2023, 'Abstract 4621: Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy', Cancer Research, 83, pp. 4621 - 4621, http://dx.doi.org/10.1158/1538-7445.am2023-4621

Chen J; Wu S; Ruan T; Slapetova I; Millar E; Lim E; Swarbrick A, 2023, 'Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD9-01

Thankamony AP; Ramkomuth S; Ramesh ST; Murali R; Chakraborty P; Karthikeyan N; Varghese BA; Jaikumar VS; Jolly MK; Swarbrick A; Nair R, 2023, 'Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1230647

Bai X; Quek C; Al-Eryani G; Harvey K; Silva I; Menzies AM; Swarbrick A; Long GV; Scolyer R; Wilmott J, 2023, 'Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy', ANNALS OF ONCOLOGY, 34, pp. S694 - S694, http://dx.doi.org/10.1016/j.annonc.2023.09.2981

Chen J; Ruan T; Wu S; Lim E; Swarbrick A, 2023, 'Targeting stromal cells to reverse immune suppression in triple-negative breast cancer', ANNALS OF ONCOLOGY, 34, pp. S190 - S190, http://dx.doi.org/10.1016/j.annonc.2023.09.1514

Masle-Farquhar E; Jackson KJL; Peters TJ; Al-Eryani G; Singh M; Payne KJ; Rao G; Avery DT; Apps G; Kingham J; Jara CJ; Skvortsova K; Swarbrick A; Ma CS; Suan D; Uzel G; Chua I; Leiding JW; Heiskanen K; Preece K; Kainulainen L; O'Sullivan M; Cooper MA; Seppänen MRJ; Mustjoki S; Brothers S; Vogel TP; Brink R; Tangye SG; Reed JH; Goodnow CC, 2022, 'STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation', Immunity, 55, pp. 2386 - 2404.e8, http://dx.doi.org/10.1016/j.immuni.2022.11.001

Deng N; Minoche A; Harvey K; Li M; Winkler J; Goga A; Swarbrick A, 2022, 'Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models', Breast Cancer Research, 24, http://dx.doi.org/10.1186/s13058-022-01540-0

Baldwin LA; Bartonicek N; Yang J; Wu SZ; Deng N; Roden DL; Chan CL; Al-Eryani G; Zanker DJ; Parker BS; Swarbrick A; Junankar S, 2022, 'DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34041-x

Papanicolaou M; Parker AL; Yam M; Filipe EC; Wu SZ; Chitty JL; Wyllie K; Tran E; Mok E; Nadalini A; Skhinas JN; Lucas MC; Herrmann D; Nobis M; Pereira BA; Law AMK; Castillo L; Murphy KJ; Zaratzian A; Hastings JF; Croucher DR; Lim E; Oliver BG; Mora FV; Parker BL; Gallego-Ortega D; Swarbrick A; O’Toole S; Timpson P; Cox TR, 2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7

Al-Eryani G; Swarbrick A, 2022, 'Spatial maps of genetically diverse breast cancer cells', Nature, 611, pp. 458 - 459, http://dx.doi.org/10.1038/d41586-022-03560-4

Anderson AC; Yanai I; Yates LR; Wang L; Swarbrick A; Sorger P; Santagata S; Fridman WH; Gao Q; Jerby L; Izar B; Shang L; Zhou X, 2022, 'Spatial transcriptomics', Cancer Cell, 40, pp. 895 - 900, http://dx.doi.org/10.1016/j.ccell.2022.08.021

Roden D; Swarbrick A, 2022, 'Mapping the cancer cell states conserved across solid tumors', Nature Genetics, 54, pp. 1066 - 1067, http://dx.doi.org/10.1038/s41588-022-01151-7

Crist SB; Nemkov T; Dumpit RF; Dai J; Tapscott SJ; True LD; Swarbrick A; Sullivan LB; Nelson PS; Hansen KC; Ghajar CM, 2022, 'Publisher Correction: Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells (Nature Cell Biology, (2022), 24, 4, (538-553), 10.1038/s41556-022-00881-4)', Nature Cell Biology, 24, pp. 1177, http://dx.doi.org/10.1038/s41556-022-00945-5

Crist SB; Nemkov T; Dumpit RF; Dai J; Tapscott SJ; True LD; Swarbrick A; Sullivan LB; Nelson PS; Hansen KC; Ghajar CM, 2022, 'Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells', Nature Cell Biology, 24, pp. 538 - 553, http://dx.doi.org/10.1038/s41556-022-00881-4

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004

Wu SZ; Roden DL; Al-Eryani G; Bartonicek N; Harvey K; Cazet AS; Chan CL; Junankar S; Hui MN; Millar EA; Beretov J; Horvath L; Joshua AM; Stricker P; Wilmott JS; Quek C; Long GV; Scolyer RA; Yeung BZ; Segara D; Mak C; Warrier S; Powell JE; O’Toole S; Lim E; Swarbrick A, 2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z

Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ, 2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23, http://dx.doi.org/10.1186/s13058-021-01461-4

Meyer B; Clifton S; Locke W; Luu PL; Du Q; Lam D; Armstrong NJ; Kumar B; Deng N; Harvey K; Swarbrick A; Ganju V; Clark SJ; Pidsley R; Stirzaker C, 2021, 'Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer', Clinical Epigenetics, 13, http://dx.doi.org/10.1186/s13148-021-01210-6

Andersson A; Larsson L; Stenbeck L; Salmén F; Ehinger A; Wu SZ; Al-Eryani G; Roden D; Swarbrick A; Borg Å; Frisén J; Engblom C; Lundeberg J, 2021, 'Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-26271-2

Wu SZ; Al-Eryani G; Roden DL; Junankar S; Harvey K; Andersson A; Thennavan A; Wang C; Torpy JR; Bartonicek N; Wang T; Larsson L; Kaczorowski D; Weisenfeld NI; Uytingco CR; Chew JG; Bent ZW; Chan CL; Gnanasambandapillai V; Dutertre CA; Gluch L; Hui MN; Beith J; Parker A; Robbins E; Segara D; Cooper C; Mak C; Chan B; Warrier S; Ginhoux F; Millar E; Powell JE; Williams SR; Liu XS; O’Toole S; Lim E; Lundeberg J; Perou CM; Swarbrick A, 2021, 'A single-cell and spatially resolved atlas of human breast cancers', Nature Genetics, 53, pp. 1334 - 1347, http://dx.doi.org/10.1038/s41588-021-00911-1

Bergholtz H; Carter JM; Cesano A; Cheang MCU; Church SE; Divakar P; Fuhrman CA; Goel S; Gong J; Guerriero JL; Hoang ML; Hwang ES; Kuasne H; Lee J; Liang Y; Mittendorf EA; Perez J; Prat A; Pusztai L; Reeves JW; Riazalhosseini Y; Richer JK; Sahin Ö; Sato H; Schlam I; Sørlie T; Stover DG; Swain SM; Swarbrick A; Thompson EA; Tolaney SM; Warren SE, 2021, 'Best practices for spatial profiling for breast cancer research with the GeoMx® digital spatial profiler', Cancers, 13, http://dx.doi.org/10.3390/cancers13174456

Mulder K; Patel AA; Kong WT; Piot C; Halitzki E; Dunsmore G; Khalilnezhad S; Irac SE; Dubuisson A; Chevrier M; Zhang XM; Tam JKC; Lim TKH; Wong RMM; Pai R; Khalil AIS; Chow PKH; Wu SZ; Al-Eryani G; Roden D; Swarbrick A; Chan JKY; Albani S; Derosa L; Zitvogel L; Sharma A; Chen J; Silvin A; Bertoletti A; Blériot C; Dutertre CA; Ginhoux F, 2021, 'Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease', Immunity, 54, pp. 1883 - 1900.e5, http://dx.doi.org/10.1016/j.immuni.2021.07.007

Wu SZ; Swarbrick A, 2021, 'Single-cell advances in stromal-leukocyte interactions in cancer', Immunological Reviews, 302, pp. 286 - 298, http://dx.doi.org/10.1111/imr.12976

Holliday H; Khoury A; Swarbrick A, 2021, 'Chromatin immunoprecipitation of transcription factors and histone modifications in Comma-Dβ mammary epithelial cells', STAR Protocols, 2, http://dx.doi.org/10.1016/j.xpro.2021.100514

Holliday H; Roden D; Junankar S; Wu SZ; Baker LA; Krisp C; Chan CL; McFarland A; Skhinas JN; Cox TR; Pal B; Huntington ND; Ormandy CJ; Carroll JS; Visvader J; Molloy MP; Swarbrick A, 2021, 'Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB', Iscience, 24, http://dx.doi.org/10.1016/j.isci.2021.102072

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

McEvoy CR; Holliday H; Thio N; Mitchell C; Choong DY; Yellapu B; Leong HS; Xu H; Lade S; Browning J; Takano EA; Byrne DJ; Gill AJ; Duong CP; Li J; Fellowes AP; Fox SB; Swarbrick A; Prall OWJ, 2021, 'A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors', Laboratory Investigation, 101, pp. 26 - 37, http://dx.doi.org/10.1038/s41374-020-00484-3

Back to profile page